Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study to Determine the Efficacy and Safety of Docetaxel and Doxorubicin With INGN 201 in Locally Advanced Breast Cancer

NCT00286247 is registered in ClinicalTrials.gov with Introgen Therapeutics as lead sponsor.

NCT NCT00286247
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00286247 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study to Determine the Efficacy and Safety of Docetaxel and Doxorubicin With INGN 201 in Locally Advanced Breast Cancer
Lead sponsor
Introgen Therapeutics
Phase
Phase 2
Overall status
Completed
Start date
Not reported
Completion date
Not reported
Enrollment
60
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced breast cancer (labc)